NewAmsterdam Pharma price target raised to $52 from $47 at Scotiabank

Scotiabank analyst George Farmer raised the firm’s price target on NewAmsterdam Pharma (NAMS) to $52 from $47 and keeps an Outperform rating on the shares. Regulatory filings in the U.S. and EU are expected in the second half of 2025 and the firm believes the robust dataset sets up for likely acquisition in the near future, the analyst tells investors.